Peg-interferon plus nucleotide analogue in patients with chronic hepatitis B with low viral load

Affiliations

¹ Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. Electronic address: ankur.jindal3@gmail.com.
² Departments of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.
³ Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.

Comment

Ankur Jindal et al. Lancet Gastroenterol Hepatol. 2017 Sep.

. 2017 Sep;2(9):628.

doi: 10.1016/S2468-1253(17)30217-0.

¹ Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. Electronic address: ankur.jindal3@gmail.com.
² Departments of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.
³ Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.

No abstract available

Comment in

Peg-interferon plus nucleotide analogue in patients with chronic hepatitis B with low viral load - Authors' reply.
Jansen L, Stelma F, Niet A, Reesink HW. Jansen L, et al. Lancet Gastroenterol Hepatol. 2017 Sep;2(9):629. doi: 10.1016/S2468-1253(17)30221-2. Lancet Gastroenterol Hepatol. 2017. PMID: 28786385 No abstract available.

Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S, van Nieuwkerk CMJ, Zaaijer HL, Molenkamp R, Takkenberg RB, Koot M, Verheij J, Beuers U, Reesink HW. de Niet A, et al. Lancet Gastroenterol Hepatol. 2017 Aug;2(8):576-584. doi: 10.1016/S2468-1253(17)30083-3. Epub 2017 May 15. Lancet Gastroenterol Hepatol. 2017. PMID: 28522204 Clinical Trial.